Keyphrases
Comorbidity
100%
Disease Burden
100%
Comparative Safety
100%
Disease Treatment
100%
Comparative Efficacy
100%
Treatment Use
100%
CorEvitas Psoriasis Registry
100%
Disease Comorbidity
100%
Quality of Life
50%
Systemic Therapy
50%
Inflammatory Diseases
50%
Patient-reported Outcomes
50%
Biological Treatment
50%
Psoriasis
50%
Long-term Efficacy
50%
Disease-based
50%
Disease Duration
50%
Confounding
50%
Disease-associated
50%
Long-term Safety
50%
Body Surface Area
50%
Psoriatic Arthritis
50%
Treatment Efficacy
50%
Selection Bias
50%
Long Disease Duration
50%
Apremilast
50%
Non-biologic
50%
Descriptive Characteristics
50%
Treatment History
50%
Systemic Medications
50%
Multiple Comorbidities
50%
Investigator's Global Assessment
50%
IL-23 Inhibitors
50%
Tumour Necrosis Factor Inhibitor (TNFi)
50%
Treatment Safety
50%
IL-17 Inhibitors
50%
Multiple Therapy
50%
Channeling Bias
50%
Medicine and Dentistry
Psoriasis
100%
Disease Burden
100%
Comorbidity
100%
Disease Duration
50%
Quality of Life
25%
Cross Sectional Study
25%
Interleukin 12
25%
Combination Therapy
25%
Patient-Reported Outcome
25%
Inflammatory Disorder
25%
Body Surface
25%
Psoriatic Arthritis
25%
Demography
25%
Apremilast
25%
Systemic Therapy
25%
Interleukin 17
25%
TNF Inhibitor
25%
Diseases
25%
Immunology and Microbiology
Disease Burden
100%
Comorbidity
100%
Inflammatory Disorder
25%
Psoriatic Arthritis
25%
Surface Area
25%
Body Surface
25%
Demography
25%
TNF Inhibitor
25%
Apremilast
25%
Interleukin 12
25%
Interleukin 17
25%